Position in NVS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$477,680,674
+$27,104,838 QoQ
Shares Held
3,047,988
+3.3% QoQ
Ownership
0.160%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#8
of 1,603 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 92%
Shared 0%
None 8%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026BlackRock, Inc. holds $263,330,305,956 across 19 Drug Manufacturers - General names. NVS ranks #10 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
67,540,400 | $81,009,988,717 | |
| 2 | JNJ |
Johnson & Johnson
|
212,098,264 | $53,866,596,097 | |
| 3 | ABBV |
AbbVie Inc.
|
149,488,412 | $37,617,263,984 | |
| 4 | MRK |
Merck & Co., Inc.
|
226,999,837 | $29,169,479,049 | |
| 5 | AMGN |
Amgen Inc
|
49,362,016 | $17,874,973,223 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
121,844,108 | $15,393,784,591 | |
| 7 | PFE |
Pfizer Inc
|
529,670,433 | $12,754,464,016 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
180,384,994 | $10,393,783,345 |
All Filings in NVS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $477,680,674 | 3,047,988 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $450,575,836 | 2,949,760 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $387,151,501 | 2,808,091 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $324,473,615 | 2,530,206 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $280,882,963 | 2,321,155 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $241,676,375 | 2,167,890 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $191,112,557 | 1,963,956 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $224,048,031 | 1,947,905 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||